Ultragenyx Halves R&D Budget, Ends Drug Programs

The rare-disease drugmaker is cutting 20% of staff to reach profitability in 2027 after recent trial failures.

Updated on Nov. 4, 2026 in Biotech

Professional photograph of a single glass laboratory vessel with amber liquid on a steel bench beside an empty chair in a quiet research room. — Ultragenyx is cutting 20% of its workforce and ending several drug programs, halving its annual R&D budget to reach profitability in 2027. AI Illustration. Upload story photo >

Ultragenyx is laying off 20% of its workforce and ending several drug development programs to halve its annual R&D budget. The company disclosed the deeper-than-expected cuts after the market closed on Tuesday, November 3, 2026, following a February 2026 10% reduction.

Why it matters

The cuts are aimed at making Ultragenyx profitable in 2027 after recent setbacks, including phase 3 failures, trimmed its investigational pipeline. The shift reflects a move from pure development toward growing sales of its six commercial products.

Ultragenyx reported 1,371 employees at the end of last year, 916 of them in R&D, and plans to reach about 1,000 staff after the 20% cut. Its proposed 2027 R&D budget of $350 million is a 38% decline from its 2025 peak, with most of that spending earmarked for commercial products.

The players

Ultragenyx

A rare-disease biopharmaceutical company with six commercial products, now cutting its pipeline and workforce to reach profitability in 2027.

The details

Ultragenyx is winding down all ongoing studies of GTX-102 and ending development of UX701 for Wilson disease, a rare copper-metabolism disorder. Setrusumab failed a pair of phase 3 trials late last year, and the company's GTX-102 phase 3 trial in Angelman syndrome failed in September. The company is also reducing its real estate footprint as part of its cost-containment strategy.

February 2026: Company forecast an R&D decline and implemented a 10% workforce reduction affecting about 130 employees.
September 2026: Phase 3 Angelman syndrome trial of GTX-102 failed.
Tuesday, November 3, 2026: Ultragenyx disclosed deeper cuts after the market close.

The Tech Race

Ultragenyx's move follows a run of setbacks in its own rare-disease pipeline, leaving the company to rely on six commercial products rather than new approvals. The shift places it among biotech firms prioritizing revenue from existing drugs over the pursuit of new late-stage programs.

Patients awaiting GTX-102, UX701 or setrusumab are unlikely to see those treatments reach market, since those programs are ending or have failed. Availability of the company's existing six commercial products is not affected by the announced cuts, according to the source.

The takeaway

Watch whether Ultragenyx reports its phase 3 DTX301 results in ornithine transcarbamylase deficiency next year, the program it has kept active. Its ability to hold a pipeline of roughly five programs a year will show whether its 2027 profitability goal is realistic.